|
Dr. Druker is an Investigator of the Howard Hughes Medical Institute, Director of the Oregon Health & Science University (OHSU) Cancer Institute, and JELD-WEN Chair of Leukemia Research at OHSU. He is widely recognized for his seminal contributions to the discovery and development of Gleevac (imanitib), one of the first molecularly targeted cancer drugs used in the treatment of chronic myelogenous leukemia (CML). His role in the development of Imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology’s Dameshek Prize, the American Cancer Society’s Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, the David A. Karnofsky Award from the American Society of Clinical Oncology, and the Robert-Koch Award. He has been elected to the Institute of Medicine of the National Academies, the American Association of Physicians, and the National Academy of Sciences. Dr. Druker received his M.D. from the University of California, San Diego School of Medicine in 1981. He also trained in oncology at Harvard's Dana-Farber Cancer Institute. Dr. Druker also serves on our Board of Directors and Scientific Advisory Board. | 